160 related articles for article (PubMed ID: 3574680)
1. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
3. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
Davison SC; Hyman NM; Dehghan A; Chan K
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
[TBL] [Abstract][Full Text] [Related]
4. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
5. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
[TBL] [Abstract][Full Text] [Related]
6. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
7. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
8. Pyridostigmine levels in myasthenia gravis.
Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
[No Abstract] [Full Text] [Related]
9. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis [proceedings].
Calvey TN; Chan K
Br J Clin Pharmacol; 1977 Jun; 4(3):404P. PubMed ID: 197984
[No Abstract] [Full Text] [Related]
11. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
Henze T; Nenner M; Michaelis HC
J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
[TBL] [Abstract][Full Text] [Related]
12. Malabsorption of pyridostigmine in patients with myasthenia gravis.
Cohan SL; Dretchen KL; Neal A
Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
[TBL] [Abstract][Full Text] [Related]
13. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
[TBL] [Abstract][Full Text] [Related]
14. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
[TBL] [Abstract][Full Text] [Related]
15. Steady state kinetics of pyridostigmine in myasthenia gravis.
Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
[TBL] [Abstract][Full Text] [Related]
16. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
[No Abstract] [Full Text] [Related]
17. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of pyridostigmine.
Cohan SL; Pohlmann JL; Mikszewski J; O'Doherty DS
Neurology; 1976 Jun; 26(6 PT 1):536-9. PubMed ID: 945494
[TBL] [Abstract][Full Text] [Related]
19. The diagnosis and management of myasthenia gravis.
Walsh JC
Med J Aust; 1974 Jun; 1(25):997-1001. PubMed ID: 4369281
[No Abstract] [Full Text] [Related]
20. Response to suxamethonium during propofol-fentanyl-N2O/O2 anaesthesia in a patient with active myasthenia gravis receiving long-term anticholinesterase therapy.
Vanlinthout LE; Robertson EN; Booij LH
Anaesthesia; 1994 Jun; 49(6):509-11. PubMed ID: 8017595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]